上海莱士(002252) - 2018 Q1 - 季度业绩预告

Financial Performance - The estimated net loss attributable to shareholders for Q1 2018 is between 719.66 million and 653.35 million RMB, compared to a profit of 222.23 million RMB in the same period last year[3]. - The primary reason for the loss is significant losses from risk investments, with an expected fair value change loss of 898 million RMB, a decrease of 960 million RMB compared to the previous year, impacting net profit by 816 million RMB[4]. Revenue Impact - The implementation of the "two-invoice system" in the pharmaceutical industry has negatively affected the company's main business revenue, estimated to decrease by approximately 114 million RMB compared to the previous year[4]. - The upgrade and transformation of the production line at the wholly-owned subsidiary Zhengzhou Laisai Blood Products Co., Ltd. also contributed to a decline in main business revenue[4]. Data Reliability - The financial data provided is preliminary and may differ from the final figures disclosed in the Q1 2018 report[5].